1. Home
  2. OPRX vs ALXO Comparison

OPRX vs ALXO Comparison

Compare OPRX & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimizeRx Corporation

OPRX

OptimizeRx Corporation

N/A

Current Price

$7.68

Market Cap

167.1M

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.07

Market Cap

172.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPRX
ALXO
Founded
2006
2015
Country
United States
United States
Employees
105
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.1M
172.8M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
OPRX
ALXO
Price
$7.68
$1.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
7
Target Price
★ $12.30
$4.60
AVG Volume (30 Days)
181.3K
★ 1.3M
Earning Date
11-11-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 124.55
26.36
EPS
★ N/A
N/A
Revenue
★ $109,429,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.01
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 18.78
N/A
52 Week Low
$4.54
$0.86
52 Week High
$15.59
$2.66

Technical Indicators

Market Signals
Indicator
OPRX
ALXO
Relative Strength Index (RSI) 37.22 42.28
Support Level $7.23 $1.03
Resistance Level $8.30 $1.34
Average True Range (ATR) 0.69 0.15
MACD -0.19 -0.00
Stochastic Oscillator 38.21 27.42

Price Performance

Historical Comparison
OPRX
ALXO

About OPRX OptimizeRx Corporation

OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: